Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
MWN-AI** Summary
**Summary of Purple Biotech's CAPTN-3 Presentation at ESMO-IO 2025**
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biotechnology company focused on pioneering first-in-class therapies to combat tumor immune evasion and drug resistance, is set to present innovative preclinical data from its CAPTN-3 tri-specific antibody platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress in London from December 10-12, 2025.
The presentation, led by Dr. Hadas Reuveni on December 10 at 17:15, will highlight the unique multi-arm design of the CAPTN-3 platform—demonstrating its capacity to create tri-specific antibodies that simultaneously engage T cells, NK cells, and target tumor-associated antigens. This innovative approach aims to enhance anti-tumor activity, particularly in treatment-resistant cancers.
Gil Efron, CEO of Purple Biotech, remarked on the promising synergies observed in preclinical studies, emphasizing the potential of their lead CAPTN-3 program, IM1240, which operates within multiple PD-1 resistant cancer models. The company aims to showcase data confirming the platform's versatility through various tri-specific antibodies.
CAPTN-3 features a cleavable capping technology designed to limit therapeutic action within the tumor microenvironment, potentially improving the therapeutic window for patients. The IM1240 antibody targets the 5T4 antigen prevalent in various solid tumors, which correlates with advanced disease and poor clinical outcomes.
In addition to CAPTN-3, Purple Biotech is also advancing other candidates like CM24—a monoclonal antibody blocking CEACAM1 to combat tumor immune evasion—and NT219, a small molecule targeting IRS1/2 and STAT3, which has shown promise in combination therapies.
For further details, the presentation will be accessible on Purple Biotech’s website post-congress.
MWN-AI** Analysis
As Purple Biotech Ltd. (NASDAQ/TASE: PPBT) prepares to present new preclinical data from its CAPTN-3 tri-specific antibody platform at the ESMO-IO 2025 Annual Congress, investors should closely analyze the potential implications for the company's stock performance and market position. The positive momentum surrounding CAPTN-3, which aims to tackle treatment-resistant cancers through its unique multi-arm design, showcases its promise in immunotherapy—a sector that is continuously evolving and attracting substantial interest.
The CAPTN-3 platform's ability to engage T cells and NK cells while targeting tumor-associated antigens suggests a robust mechanism to enhance localized immune responses. Given the increasing challenges posed by tumor immune evasion and drug resistance, this innovation could attract investors looking for cutting-edge therapeutic solutions.
Market sentiment could be particularly favorable if the data presented indicates significant anti-tumor activity, which would enhance confidence in the platform's potential for commercialization. Additionally, if CAPTN-3 can effectively address PD-1 resistant models, it would further solidify Purple Biotech's positioning within the competitive oncology landscape. Given that the biotechnology sector often reacts sharply to new trial data, investors should monitor the market's reaction post-presentation.
Moreover, with other promising candidates in Purple Biotech’s pipeline, including CM24 and NT219, the company is poised to broaden its potential revenue streams. The successful outcomes of ongoing studies could catalyze future partnerships or licensing agreements, providing additional funding avenues.
In conclusion, while there are inherent risks in clinical-stage biotech investments, the upcoming data presentation may serve as a pivotal moment for Purple Biotech. Investors should remain vigilant and consider positioning themselves accordingly as data begins to flow, recognizing that positive developments in oncology can significantly impact financial valuations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers
REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom.
Presentation Details :
? Conference : ESMO Immuno-Oncology (ESMO-IO) 2025 Annual Congress
? Title : CAPTN-3 unique design demonstrated by 2 novel platform compounds
? Presenter : Dr. Hadas Reuveni
? Presentation Number : FPN# 287P
? Session Title : Poster Presentation
? Date / Time : Wednesday, December 10, 2025, 17:15
? Location : London, UK
“Our CAPTN-3 platform can produce novel tri-specific antibodies that engage T cells, NK cells and bind to tumor associated antigens. The powerful synergy we have seen in preclinical studies strengthens our conviction in not only the platform, but also in this novel structure to overcome tumor evasion and drug resistance. We look forward to showcasing new data from our lead CAPTN-3 program, IM1240, in multiple PD-1 resistant models, and new data demonstrating the platform versatility with multiple tri-specific antibodies” said Gil Efron, Chief Executive Officer of Purple Biotech, Ltd.
The poster will be accessible under the Publications section of the Purple Biotech website following the congress.
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes CAPTN-3, CM24 and NT219. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound’s therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophil extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers and other potential tissue biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients with NT219 in combination with cetuximab or pembrolizumab was initiated. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com
CONTACTS:
FAQ**
How does the unique multi-arm design of the CAPTN-3 platform contribute to its ability to overcome tumor immune evasion and resistance, specifically in the context of treatment-resistant cancers? (Purple Biotech Ltd ADR (Sponsored) Level 3 PPBT)
Can you elaborate on the preclinical data regarding IM1240's efficacy in PD-1 resistant models and how it compares to existing treatments for similar resistant cancers? (Purple Biotech Ltd ADR (Sponsored) Level 3 PPBT)
What specific advantages does the cleavable capping technology of CAPTN-3 offer in enhancing the therapeutic window for patients, and how might this be reflected in clinical outcomes? (Purple Biotech Ltd ADR (Sponsored) Level 3 PPBT)
How does Purple Biotech plan to leverage the versatility of its CAPTN-3 platform with multiple tri-specific antibodies in future clinical trials, particularly in various solid tumor types? (Purple Biotech Ltd ADR (Sponsored) Level 3 PPBT)
**MWN-AI FAQ is based on asking OpenAI questions about Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ: PPBT).
NASDAQ: PPBT
PPBT Trading
-0.55% G/L:
$4.53 Last:
4,010 Volume:
$4.55 Open:
